Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Barreiro, Antonio
• dc.contributor.author Sisteré-Oró, Marta
• dc.contributor.author Cebollada Rica, Paula
• dc.contributor.author Meyerhans, Andreas
• dc.contributor.author Ferrer, Laura
• dc.date.accessioned 2023-05-26T06:32:49Z
• dc.date.available 2023-05-26T06:32:49Z
• dc.date.issued 2023
• dc.description.abstract Current COVID-19 vaccines have been associated with a decline in infection rates, prevention of severe disease, and a decrease in mortality rates. However, SARS-CoV-2 variants are continuously evolving, and development of new accessible COVID-19 vaccines is essential to mitigate the pandemic. Here, we present data on preclinical studies in mice of a receptor-binding domain (RBD)-based recombinant protein vaccine (PHH-1V) consisting of an RBD fusion heterodimer comprising the B.1.351 and B.1.1.7 SARS-CoV-2 variants formulated in SQBA adjuvant, an oil-in-water emulsion. A prime-boost immunisation with PHH-1V in BALB/c and K18-hACE2 mice induced a CD4+ and CD8+ T cell response and RBD-binding antibodies with neutralizing activity against several variants, and also showed a good tolerability profile. Significantly, RBD fusion heterodimer vaccination conferred 100% efficacy, preventing mortality in SARS-CoV-2 infected K18-hACE2 mice, but also reducing Beta, Delta and Omicron infection in lower respiratory airways. These findings demonstrate the feasibility of this recombinant vaccine strategy.
• dc.description.sponsorship This project was partially funded by the Center for the Development of Industrial Technology (CDTI, IDI20210115), a public organization answering to the Spanish Ministry of Science and Innovation. Javier Iglesias-Fernández is supported by the Torres Quevedo Programme grant no. PTQ2020-011291 by the Spanish Ministry of Science and Innovation.
• dc.format.mimetype application/pdf
• dc.identifier.citation Barreiro A, Prenafeta A, Bech-Sabat G, Roca M, Perozo Mur E, March R, et al. Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2. iScience. 2023 Mar 17;26(3):106126. DOI: 10.1016/j.isci.2023.106126
• dc.identifier.doi http://dx.doi.org/10.1016/j.isci.2023.106126
• dc.identifier.issn 2589-0042
• dc.identifier.uri http://hdl.handle.net/10230/56976
• dc.language.iso eng
• dc.publisher Elsevier
• dc.relation.ispartof iScience. 2023 Mar 17;26(3):106126
• dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/PTQ2020-011291
• dc.rights © 2023 The Author(s). This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
• dc.subject.keyword Health sciences
• dc.subject.keyword Immune response
• dc.subject.keyword Immunology
• dc.subject.keyword Microbiology
• dc.title Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion